Optimistic Outlook on Sera Prognostics: A Compelling Buy Amidst Positive Developments

William Blair analyst Andrew Brackmann has maintained their bullish stance on SERA stock, giving a Buy rating on May 7.

Andrew Brackmann’s rating is based on several encouraging developments at Sera Prognostics. The company is making strides in increasing physician awareness and adoption of its PreTRM test, which is crucial for its market penetration. Additionally, there have been positive updates regarding payer coverage and efforts to include the test in clinical guidelines, which are important for long-term growth.
Brackmann believes that Sera Prognostics has a significant opportunity ahead with the commercialization of its PreTRM test. He anticipates that the company’s shares could see substantial growth over time, driven by potential catalysts in the coming quarters and years. The expectation of increased volume and revenue growth further supports his optimistic outlook, making the stock a compelling buy.

Brackmann covers the Healthcare sector, focusing on stocks such as NeoGenomics, Guardant Health, and QuidelOrtho. According to TipRanks, Brackmann has an average return of -3.6% and a 27.27% success rate on recommended stocks.